Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenosine‑5′‑Rp‑alpha‑thio‑triphosphate is a synthetic, non-hydrolyzable analog of adenosine triphosphate (ATP) in which one of the oxygen atoms in the triphosphate chain is replaced by sulfur. This modification makes it resistant to hydrolysis by most ATPases and phosphatases, allowing it to act as a stable mimic of ATP in biochemical studies. It is commonly used as an experimental tool to study ATP-dependent enzyme systems, including kinases and adenylyl cyclase, where it can serve as both a substrate and an inhibitor. Once incorporated into proteins via thiophosphorylation, these proteins become resistant to dephosphorylation by protein phosphatases[3][4][6][7]. The compound has no approved medical indications and is primarily used for laboratory research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adenosine-5'-rp-alpha-thio-triphosphate.